



December 2, 2015

ImmunoGen, Inc. Announces Oppenheimer 26th Annual Healthcare Conference Webcast

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that David Johnston, Executive Vice President and Chief Financial Officer, will present at the upcoming Oppenheimer 26th Annual Healthcare Conference. The presentation is scheduled for 2:45 pm ET on December 9, 2015.

This webcast will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α -positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcylo[®]. More information about the Company can be found at www.immunogen.com.

Kadcylo[®] is a registered trademark of Genentech, a member of the Roche Group.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20151202005105/en/>

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media